Mixed phenotype acute leukemia: current approaches to diagnosis and treatment
TB Alexander, E Orgel - Current Oncology Reports, 2021 - Springer
Abstract Purpose of Review Mixed phenotype acute leukemia (MPAL) is a rare subtype of
acute leukemia with features of both acute lymphoblastic leukemia (ALL) and acute myeloid …
acute leukemia with features of both acute lymphoblastic leukemia (ALL) and acute myeloid …
[HTML][HTML] Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies
The outcome of B-cell precursor acute lymphoblastic leukemia (ALL) is different in children
and adults, with overall survival (OS) rates at 5 years ranging from 90% to 45%. 1, 2 …
and adults, with overall survival (OS) rates at 5 years ranging from 90% to 45%. 1, 2 …
Lineage conversion in pediatric B-cell precursor acute leukemia under blinatumomab therapy
A Semchenkova, E Mikhailova, A Komkov… - International Journal of …, 2022 - mdpi.com
We report incidence and deep molecular characteristics of lineage switch in 182 pediatric
patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were …
patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were …
Mixed-phenotype acute leukemia: clinical diagnosis and therapeutic strategies
BS George, B Yohannan, A Gonzalez, A Rios - Biomedicines, 2022 - mdpi.com
Mixed-phenotype acute leukemia (MPAL) comprises a heterogenous group of leukemias
that are genetically, immunophenotypically, and clinically, diverse. Given the rarity of the …
that are genetically, immunophenotypically, and clinically, diverse. Given the rarity of the …
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
P Chauvet, A Paviglianiti, M Labopin… - Bone marrow …, 2023 - nature.com
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of …
Mixed phenotype/lineage leukemia: has anything changed for 2021 on diagnosis, classification, and treatment?
MC Béné, A Porwit - Current Oncology Reports, 2022 - Springer
Abstract Purpose of Review Recent advances in the small field of the rare mixed phenotype
acute leukemias (MPAL) are presented focusing on a better understanding of their …
acute leukemias (MPAL) are presented focusing on a better understanding of their …
Pediatric mixed-phenotype acute leukemia: what's new?
S Batra, AJ Ross - Cancers, 2021 - mdpi.com
Simple Summary Pediatric mixed-phenotype leukemia is a rare form of blood cancer in
children. In this review, we cover both the evolution of treatment over the past several years …
children. In this review, we cover both the evolution of treatment over the past several years …
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute …
Mixed-phenotype acute leukemia (MPAL) is a rare disease. Treatment is often similar to that
of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic …
of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic …
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell …
C Papayannidis, C Sartor, A Dominietto… - Hematological …, 2021 - Wiley Online Library
Despite progresses in the treatment of B‐cell acute lymphoblastic leukemia (B‐ALL), relapse
after allogeneic Stem Cell Transplant (allo‐SCT) frequently occurs, and prognosis is dismal …
after allogeneic Stem Cell Transplant (allo‐SCT) frequently occurs, and prognosis is dismal …
Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia
Simple Summary Childhood acute lymphoblastic leukemia (ALL) has seen significant
advances in treatment, yet children classified as high-risk still face challenging outcomes …
advances in treatment, yet children classified as high-risk still face challenging outcomes …